Cancer Chemotherapy Regimen for Ovarian Cancer
H-CMF ovarian(116) _________________________________________________________________ hexamethylmelami 150 mg/day orally from day 1 to day 14. cytoxan......... 150 mg/day orally from day 1 to day 14. methotrexate.... 40 mg/sqm IV on day 1 and day 8. fluorouracil.... 600 mg/sqm IV on day 1 and day 8. FREQUENCY....... Repeat cycle every 28 days. reference... Young RC. Chabner BA. Hubbard SP. Fisher RI. Bender RA. Anderson T. Simon RM. Canellos GP. DeVita VT Jr. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New England Journal of Medicine. 299(23):1261-6, 1978 Dec 7. abstract... Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan. Treatment with the four-drug combination was associated with a significantly increased overall response rate (75 vs. 54 per cent) (P less than 0.05), more complete remissions (33 vs. 16 per cent) and longer median survival (29 vs. 17 months) (P less than 0.02) but more severe toxicity than occurred with melphalan. Patients with minimal residual disease had a significantly higher overall response rate than patients with extensive residual disease (84 vs. 53 per cent) (P less than 0.05). Patients with advanced disease who achieved a complete remission documented by peritoneoscopy or laparotomy (or both) have a median survival that will exceed three years. The four-drug regimen is more effective than melphalan in the management of advanced ovarian adenocarcinoma.
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community
Editorial activities: Publish, peer review, edit online articles.
Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.